The following was written and posted by Paul Edwards to the Advanced Prostate Cancer Online Support Group: The March 2014 issue of the Asia-Pacific Journal of Clinical Oncology published an article “Why do some cancer patients receiving chemotherapy choose to take complementary and alternative medicines and what are the risks?” by authors from University of Queensland [...]
Yesterday’s post was about the use of chemotherapy (with docetaxel) for the treatment of men with advanced prostate cancer who were 80 years old or older. Today’s post is about the use of chemotherapy in men 60 years or younger. The research for both of these posts was performed by the same team of scientists [...]
Chemotherapy (chemo with docetaxel) has a reputation for being a difficult therapy loaded with many side effects. I believe that this reputation is overblown given that all of our new non-chemotherapies (other than Provenge) come with their own list of significant side effects. However, its reputation is in the minds of many, so men who [...]
Over the past two to three years there have been some small studies that have indicated that the use of concomitant anticoagulants along with docetaxel (chemotherapy) may improve overall survival The most recent examination of this issue was performed by a team led by Emmanuel S. Antonarakis, MD, of Johns Hopkins University in Baltimore. They [...]
Chemotherapy using docetaxel remains an important therapy, despite the newly approved drugs, to treat hormone refractory prostate cancer. Chemotherapy improves survival, however, all men taking it will eventually become refractory to the treatment. Zoledronic acid (ZA) is the most potent member of nitrogen-containing bisphosphonate family and has anti-tumor activity in prostate cancer. In a study, [...]